Development of technological platform for obtaining nanostructured systems with potential in the treatment of neglected diseases

• Grant number: 14/00638-8
• Support Opportunities: Regular Research Grants
• Start date: May 01, 2014
• End date: April 30, 2016
• Field of knowledge: Health Sciences - Pharmacy - Pharmaceutical Technology
• Principal Investigator: Nádia Araci Bou-Chacra
• Grantee: Nádia Araci Bou-Chacra
• Host Institution: Faculdade de Ciências Farmacêuticas (FCF). Universidade de São Paulo (USP). São Paulo , SP, Brazil
• Associated researchers: Laura de Oliveira Nascimento ; Paulo Cesar Cotrim
• Associated research grant(s): 14/50327-9 - Development of technology platform for obtaining nanostructured systems with potential application in the treatment of neglected diseases, AP.R

Abstract

Neglected diseases (NDs) are diseases usually transmitted with a higher incidence in developing or emerging countries. These diseases affect vulnerable populations in those countries where poor sanitation and lack of access to health care to facilitate their transmission, as well as the proliferation of vectors. Among these the NDs, leishmaniasis ranks second in mortality caused by neglected tropical diseases. In the case of malaria, an estimated 110 million new cases each year and deaths between one and two million. In 2011, 8.7 million people became ill with tuberculosis and 1.4 million died because of this disease. Thus, the search for treatments with high therapeutic efficacy, greater safety and shorter duration for patients affected by neglected diseases is urgent. In this sense, nanostructured systems have shown great potential for application in the development of innovative medicines. Among the methods of obtaining such systems, one stands out by high-pressure homogenization. This method, among other advantages, allows obtaining nanostructured lipid carriers and nanocrystals on an industrial scale. These systems have the advantage of raising the therapeutic efficacy and safety of medicines. The objective of this work is to develop a technology platform for obtaining nanostructured with potential application in the treatment of neglected diseases systems. As drugs model for the development of the platform artemether and rifampicin, as well as the drug candidates and orotic acid buparvaquone will be used. (AU)